| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
18-Methoxycoronaridine targets the α3β4 nicotinic acetylcholine receptor as a potent antagonist. It is also described as an allosteric modulator of α3β4 nicotinic receptors. The compound is a derivative of ibogaine with improved selectivity and safety profile. Unlike ibogaine, 18-MC shows minimal off-target activity at cardiac ion channels, providing a significantly improved therapeutic index for potential clinical applications.
|
|---|---|
| ln Vitro |
In vitro activity data for 18-methoxycoronaridine demonstrate potent antagonism at α3β4 nicotinic acetylcholine receptors. The compound shows high selectivity for α3β4 over other nicotinic receptor subtypes, contributing to its improved safety profile. No specific IC50 values are provided in the available literature, but the compound is characterized as a potent antagonist based on functional assay data. It exhibits a clean selectivity profile with minimal off-target activity.
|
| ln Vivo |
In vivo activity data for 18-methoxycoronaridine include completed Phase 1 clinical trials demonstrating safety and tolerability. The compound is currently in Phase 2 clinical investigation (NCT03084952) for cutaneous leishmaniasis. It shows a greater than 12-fold cardiac safety margin compared to ibogaine, indicating favorable in vivo safety pharmacology. No specific efficacy data from animal models are detailed in the available literature.
|
| Enzyme Assay |
No published experimental protocols for cell-free enzyme/receptor binding assays are available for 18-methoxycoronaridine. For related nicotinic receptor antagonists, standard binding assays involve incubation of membrane preparations from cells expressing α3β4 nAChR with radiolabeled ligands (e.g., [³H]epibatidine) and competing compound at concentrations of 0.1 nM to 100 μM, incubation at 25°C for 60-120 minutes, filtration through GF/B filters, and scintillation counting to determine Ki values from competition curves.
|
| Cell Assay |
No published in vitro cell-based experimental protocols are available specifically for 18-methoxycoronaridine. For related nicotinic receptor functional assays, standard protocols involve calcium flux measurements using fluorescent indicators (e.g., Fluo-4) in cells expressing α3β4 nAChR, compound treatment at concentrations of 0.01-100 μM, agonist-induced calcium response monitoring, and calculation of inhibition potency (IC50) from concentration-response curves using plate readers with fluorescence detection.
|
| Animal Protocol |
No published in vivo animal experimental protocols are available specifically for 18-methoxycoronaridine. For related clinical pharmacology studies, standard protocols involve single and multiple ascending dose administration in healthy volunteers (Phase 1) at doses of 1-100 mg via oral or intravenous routes, with serial blood sampling (0-72 hours) for pharmacokinetic analysis, continuous cardiac monitoring (ECG) for safety assessment, and adverse event recording. Phase 2 protocols involve dosing in patient populations with efficacy endpoints measured over 4-12 weeks.
|
| Additional Infomation |
18-Methoxycoronary glycoside is being investigated in the clinical trial NCT03084952 (a phase 2 trial evaluating the efficacy, safety, and tolerability of 18-methoxycoronary glycoside in patients with cutaneous leishmaniasis).
|
| Molecular Formula |
C22H28N2O3
|
|---|---|
| Exact Mass |
368.21
|
| CAS # |
308123-60-6
|
| Related CAS # |
266686-77-5 (HCl);308123-60-6;
|
| PubChem CID |
15479177
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.257g/cm3
|
| Boiling Point |
510.092ºC at 760 mmHg
|
| Flash Point |
262.295ºC
|
| Index of Refraction |
1.63
|
| LogP |
2.819
|
| tPSA |
54.56
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
584
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COCCC1CC2CC3(C1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC
|
| InChi Key |
DTJQBBHYRQYDEG-SVBQBFEESA-N
|
| InChi Code |
InChI=1S/C22H28N2O3/c1-26-10-8-15-11-14-12-22(21(25)27-2)19-17(7-9-24(13-14)20(15)22)16-5-3-4-6-18(16)23-19/h3-6,14-15,20,23H,7-13H2,1-2H3/t14-,15+,20+,22-/m1/s1
|
| Chemical Name |
methyl (6S,6aS,7R,9R)-7-(2-methoxyethyl)-7,8,9,10,12,13-hexahydro-5H-6,9-methanopyrido[1',2'
|
| Synonyms |
18Methoxycoronaridine18-Methoxycoronaridine 18 Methoxycoronaridine 18 MC 18MC18-MC
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT04292197
Conditions:AddictionLink: https://clinicaltrials.gov/ct2/show/NCT03084952
Conditions:Leishmaniasis; American, Cutaneous|Drug Side EffectProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
